Windtree Therapeutics Inc

WINT

Company Profile

  • Business description

    Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

  • Contact

    2600 Kelly Road
    Suite 100
    WarringtonPA18976-3622
    USA

    T: +1 215 488-9300

    E: [email protected]

    https://www.windtreetx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    14

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,779.905.100.06%
CAC 407,627.2911.300.15%
DAX 4023,629.5712.01-0.05%
Dow JONES (US)43,089.02507.241.19%
FTSE 1008,787.0028.010.32%
HKSE24,481.13304.061.26%
NASDAQ19,912.53281.561.43%
Nikkei 22538,942.07151.510.39%
NZX 50 Index12,460.966.52-0.05%
S&P 5006,092.1867.011.11%
S&P/ASX 2008,559.203.700.04%
SSE Composite Index3,455.9735.411.04%

Market Movers